Nucleoside/nucleotide analog inhibitors of hepatitis B virus polymerase: Mechanism of action and resistance

Current Opinion in Virology

Volumn 8, Issue , 2014, Pages 1-9

  Menéndez Arias, Luis ^a   Álvarez, Mar ^a   Pacheco, Beatriz ^a  

^a CENTRO DE BIOLOGÍA MOLECULAR SEVERO OCHOA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; CLEVUDINE; EMTRICITABINE; ENTECAVIR; LAMIVUDINE; TELBIVUDINE; TENOFOVIR; ANTIVIRUS AGENT; DNA DIRECTED DNA POLYMERASE; NUCLEOSIDE; NUCLEOTIDE;

ARTICLE; DISEASE COURSE; DNA REPLICATION; DNA SYNTHESIS; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIVER INJURY; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; THERAPY; ANTIVIRAL RESISTANCE; DRUG EFFECTS; ENZYMOLOGY; GENETICS; METABOLISM; MISSENSE MUTATION;

ANTIVIRAL AGENTS; DNA-DIRECTED DNA POLYMERASE; DRUG RESISTANCE, VIRAL; HEPATITIS B VIRUS; HUMANS; MUTATION, MISSENSE; NUCLEOSIDES; NUCLEOTIDES;

EID: 84901021045     PISSN: 18796257     EISSN: 18796265     Source Type: Journal    
DOI: 10.1016/j.coviro.2014.04.005     Document Type: Review

References (93)

1. J. Lucifora, and F. Zoulim The life cycle of hepatitis B virus and antiviral targets Future Virol 6 2011 599 614
2. D. Glebe, and C.M. Bremer The molecular virology of hepatitis B virus Semin Liver Dis 33 2013 103 112
3. S.J. Hadziyannis, D. Vassilopoulos, and E. Hadziyannis The natural course of chronic hepatitis B virus infection and its management Adv Pharmacol 67 2013 247 291
4. M. Nassal Hepatitis B viruses: reverse transcription a different way Virus Res 134 2008 235 249
5. O. Poch, I. Sauvaget, M. Delarue, and N. Tordo Identification of four conserved motifs among the RNA-dependent polymerase encoding elements EMBO J 8 1989 3867 3874 (Pubitemid 20016069)
6. L.J. Stuyver, S.A. Locarnini, A. Lok, D.D. Richman, W.F. Carman, J.L. Dienstag, and R.F. Schinazi Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region Hepatology 33 2001 751 757 (Pubitemid 32185239)
7. S.A. Jones, and J. Hu Protein-primed terminal transferase activity of hepatitis B virus polymerase J Virol 87 2013 2563 2576 Erratum in: J Virol 2013, 87:12505
8. G. Radziwill, W. Tucker, and H. Schaller Mutational analysis of the hepatitis B virus P gene product: domain structure and RNase H activity J Virol 64 1990 613 620 (Pubitemid 20032673)
9. S.A. Jones, R. Boregowda, T.E. Spratt, and J. Hu In vitro epsilon RNA-dependent protein priming activity of human hepatitis B virus polymerase J Virol 86 2012 5134 5150 Erratum in: J Virol 2013, 87:12504
10. J.E. Tavis, B. Massey, and Y. Gong The duck hepatitis B virus polymerase is activated by its RNA packaging signal, J Virol 72 1998 5789 5796 (Pubitemid 28283364)
11. J. Vörös, A. Urbanek, G.J.P. Rautureau, M. O'Connor, H.C. Fisher, A.E. Ashcroft, and N. Ferguson Large-scale production and structural and biophysical characterizations of the human hepatitis B virus polymerase J Virol 88 2014 2584 2599
12. T.M. Abraham, and D.D. Loeb The topology of hepatitis B virus pregenomic RNA promotes its replication J Virol 81 2007 11577 11584 (Pubitemid 47623789)
13. D.R. Langley, A.W. Walsh, C.J. Baldick, B.J. Eggers, R.E. Rose, S.M. Levine, A.J. Kapur, R.J. Colonno, and D.J. Tenney Inhibition of hepatitis B virus polymerase by entecavir J Virol 81 2007 3992 4001 (Pubitemid 46586894)
14. E.P. Tchesnokov, A. Obikhod, R.F. Schinazi, and M. Götte Delayed chain termination protects the anti-hepatitis B virus drug entecavir from excision by HIV-1 reverse transcriptase J Biol Chem 283 2008 34218 34228
15. S.A. Jones, E. Murakami, W. Delaney, P. Furman, and J. Hu Noncompetitive inhibition of hepatitis B virus reverse transcriptase protein priming and DNA synthesis by the nucleoside analog clevudine Antimicrob Agents Chemother 57 2013 4181 4189 Erratum in: Antimicrob Agents Chemother 2013, 57:5788
16. R. Gironés, and R.H. Miller Mutation rate of the hepadnavirus genome Virology 170 1989 595 597 (Pubitemid 19162574)
17. A.S. Lok, C.L. Lai, N. Leung, G.B. Yao, Z.Y. Cui, E.R. Schiff, J.L. Dienstag, E.J. Heathcote, N.R. Little, and D.A. Griffiths et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B Gastroenterology 125 2003 1714 1722 (Pubitemid 37500436)
18. S.J. Hadziyannis, N.C. Tassopoulos, E.J. Heathcote, T.T. Chang, G. Kitis, M. Rizzetto, P. Marcellin, S.G. Lim, Z. Goodman, and J. Ma et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years Gastroenterology 131 2006 1743 1751 (Pubitemid 44958517)
19. W.K. Seto, C.L. Lai, J. Fung, D.K. Wong, J.C. Yuen, I.F. Hung, and M.F. Yuen Significance of HBV DNA levels at 12 weeks of telbivudine treatment and the 3 years treatment outcome J Hepatol 55 2011 522 528
20. T.T. Chang, C.L. Lai, S. Kew Yoon, S.S. Lee, H.S. Coelho, F.J. Carrilho, F. Poordad, W. Halota, Y. Horsmans, and N. Tsai et al. Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B Hepatology 51 2010 422 430
21. P. Marcellin, E. Gane, M. Buti, N. Afdhal, W. Sievert, I.M. Jacobson, M.K. Washington, G. Germanidis, J.F. Flaherty, and R.A. Schall et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study Lancet 381 2013 468 475
22. K.M. Kitrinos, A. Corsa, Y. Liu, J. Flaherty, A. Snow-Lampart, P. Marcellin, K. Borroto-Esoda, and M.D. Miller No detectable resistance to tenofovir disoproxil fumarate after 6 years of therapy in patients with chronic hepatitis B Hepatology 59 2014 434 442
23. N. Warner, S. Locarnini, M. Kuiper, A. Bartholomeusz, A. Ayres, L. Yuen, and T. Shaw The L80I substitution in the reverse transcriptase domain of the hepatitis B virus polymerase is associated with lamivudine resistance and enhanced viral replication in vitro Antimicrob Agents Chemother 51 2007 2285 2292 (Pubitemid 47047302)
24. S.Y. Rhee, S. Margeridon-Thermet, M.H. Nguyen, T.F. Liu, R.M. Kagan, B. Beggel, J. Verheyen, R. Kaiser, and R.W. Shafer Hepatitis B virus reverse transcriptase sequence variant database for sequence analysis and mutation discovery Antiviral Res 88 2010 269 275
25. J. Ma, Y. Zhang, X. Chen, Y. Jin, D. Chen, Y. Wu, J. Cui, H. Wang, J. Liu, N. Li, and F. Gao Association of preexisting drug-resistance mutations and treatment failure in hepatitis B patients PLoS ONE 8 2013 e67606
26. E. Karatayli, S. Karayalçin, H. Karaaslan, H. Kayhan, A.R. Türkyilmaz, F. Sahin, C. Yurdaydin, and A.M. Bozdayi A novel mutation pattern emerging during lamivudine treatment shows cross-resistance to adefovir dipivoxil treatment Antivir Ther 12 2007 761 768 (Pubitemid 47235490)
27. H. Yatsuji, C. Noguchi, N. Hiraga, N. Mori, M. Tsuge, M. Imamura, S. Takahashi, E. Iwao, Y. Fujimoto, and H. Ochi et al. Emergence of a novel lamivudine-resistant hepatitis B virus variant with a substitution outside the YMDD motif Antimicrob Agents Chemother 50 2006 3867 3874 (Pubitemid 44684905)
28. R. Ling, D. Mutimer, M. Ahmed, E.H. Boxall, E. Elias, G.M. Dusheiko, and T.J. Harrison Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine Hepatology 24 1996 711 713 (Pubitemid 26296020)
29. M.I. Allen, M. Deslauriers, C.W. Andrews, G.A. Tipples, K.-A. Walters, D.L.J. Tyrrell, N. Brown, for the Lamivudine Clinical Investigation Group, and L.D. Condreay Identification and characterization of mutations in hepatitis B virus resistant to lamivudine Hepatology 27 1998 1670 1677 (Pubitemid 28264693)
30. R.K. Gaillard, J. Barnard, V. Lopez, P. Hodges, E. Bourne, L. Johnson, M.I. Allen, P. Condreay, W.H. Miller, and L.D. Condreay Kinetic analysis of wild-type and YMDD mutant hepatitis B virus polymerases and effects of deoxyribonucleotide concentrations on polymerase activity Antimicrob Agents Chemother 46 2002 1005 1013 (Pubitemid 34260343)
31. F. Tacke, C. Gehrke, T. Luedde, A. Heim, M.P. Manns, and C. Trautwein Basal core promoter and precore mutations in the hepatitis B virus genome enhance replication efficacy of lamivudine-resistant mutants J Virol 78 2004 8524 8535 (Pubitemid 39025118)
32. Y. Liu, Z. Xu, Y. Wang, X. Li, L. Liu, L. Chen, S. Xin, and D. Xu rtM204Q may serve as a novel lamivudine-resistance-associated mutation of hepatitis B virus PLoS ONE 9 2014 e89015
33. B. Zöllner, M. Sterneck, K. Wursthorn, J. Petersen, M. Schröter, R. Laufs, and H.H. Feucht Prevalence, incidence, and clinical relevance of the reverse transcriptase V207I mutation outside the YMDD motif of the hepatitis B virus polymerase during lamivudine therapy J Clin Microbiol 43 2005 2503 2505 (Pubitemid 40656280)
34. M. Sede, D. Ojeda, L. Cassino, G. Westergaard, M. Vazquez, S. Benetti, F. Fay, H. Tanno, and J. Quarleri Long-term monitoring drug resistance by ultra-deep pyrosequencing in a chronic hepatitis B virus (HBV)-infected patient exposed to several unsuccessful therapy schemes Antiviral Res 94 2012 184 187
35. C.L. Lin, R.N. Chien, C.C. Hu, M.W. Lai, and C.T. Yeh Identification of hepatitis B virus rtS117F substitution as a compensatory mutation for rtM204I during lamivudine therapy J Antimicrob Chemother 67 2012 39 48
36. S.B. Pai, A.M. Bozdayi, R.B. Pai, T. Beker, M. Sarioglu, A.R. Turkyilmaz, J. Grier, C. Yurdaydin, and R.F. Schinazi Emergence of a novel mutation in the FLLA region of hepatitis B virus during lamivudine therapy Antimicrob Agents Chemother 49 2005 2618 2624 (Pubitemid 40917570)
37. R. Gerolami, M. Bourliere, P. Colson, P. Halfon, P. Borentain, M. Henry, D. Botta, V. Thibault, H. Khiri, and C. Tamalet Unusual selection of rtA181V HBV mutants cross-resistant to adefovir following prolonged lamivudine monotherapy: report of two cases Antivir Ther 11 2006 1103 1106 (Pubitemid 44955187)
38. S. Amini-Bavil-Olyaee, J. Sheldon, T. Lutz, C. Trautwein, and F. Tacke Molecular analysis of an HBsAg-negative hepatitis B virus mutant selected in a tenofovir-treated HIV-hepatitis B virus co-infected patient AIDS 23 2009 268 272
39. D.J. Tenney, R.E. Rose, C.J. Baldick, S.M. Levine, K.A. Pokornowski, A.W. Walsh, J. Fang, C.F. Yu, S. Zhang, and C.E. Mazzucco et al. Two-year assessment of entecavir resistance in lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present Antimicrob Agents Chemother 51 2007 902 911 (Pubitemid 46355274)
40. A.M. Bozdayi, O. Uzunalimoǧlu, A.R. Türkyilmaz, N. Aslan, O. Sezgin, T. Sahin, G. Bozdayi, K. Cinar, S.B. Pai, and R. Pai et al. YSDD: a novel mutation in HBV DNA polymerase confers clinical resistance to lamivudine J Viral Hepat 10 2003 256 265 (Pubitemid 36801911)
41. O. Schildgen, C.K. Schewe, M. Vogel, M. Däumer, R. Kaiser, L. Weitner, B. Matz, and J.K. Rockstroh Successful therapy of hepatitis B with tenofovir in HIV-infected patients failing previous adefovir and lamivudine treatment AIDS 18 2004 2325 2327 (Pubitemid 39620226)
42. D. Ji, Y. Liu, L. Li, Z. Xu, L.L. Si, J.Z. Dai, X. Li, L. Wang, Z. Yao, and S.J. Xin et al. The rtL229 substitutions in the reverse transcriptase region of hepatitis B virus (HBV) polymerase are potentially associated with lamivudine resistance as a compensatory mutation J Clin Virol 54 2012 66 72
43. B. Qin, B. Zhang, X. Zhang, T. He, W. Xu, L. Fu, and C. Tu Substitution rtq267h of hepatitis B virus increases the weight of replication and lamivudine resistance Hepat Mon 13 2013 e12160
44. Y.S. Lee, Y.H. Chung, J.A. Kim, S.E. Kim, J.W. Shin, K.M. Kim, Y.S. Lim, N.H. Park, H.C. Lee, Y.S. Lee, and D.J. Suh Hepatitis B virus with the rtL80V/I mutation is associated with a poor response to adefovir dipivoxil therapy Liver Int 29 2009 552 556
45. S. Villet, C. Pichoud, G. Billioud, L. Barraud, S. Durantel, C. Trépo, and F. Zoulim Impact of hepatitis B virus rtA181V/T mutants on hepatitis B treatment failure J Hepatol 48 2008 747 755
46. S.K. Fung, P. Andreone, S.H. Han, K.R. Reddy, A. Regev, E.B. Keeffe, M. Hussain, C. Cursaro, P. Richtmyer, J.A. Marrero, and A.S.F. Lok Adefovir-resistant hepatitis B can be associated with viral rebound and hepatic decompensation J Hepatol 43 2005 937 943 (Pubitemid 41627977)
47. K. Borroto-Esoda, M.D. Miller, and S. Arterburn Pooled analysis of amino acid changes in the HBV polymerase in patients from four major adefovir dipivoxil clinical trials J Hepatol 47 2007 492 498 (Pubitemid 47334760)
48. L.J. Liu, J.H. Wang, S.C. Du, J.H. Tian, R.F. Yang, and L. Wei rtE218G, a novel hepatitis B virus mutation with resistance to adefovir dipivoxil in patients with chronic hepatitis B J Viral Hepat 17 Suppl 1 2010 66 72
49. P. Angus, R. Vaughan, S. Xiong, H. Yang, W. Delaney, C. Gibbs, C. Brosgart, D. Colledge, R. Edwards, and A. Ayres et al. Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase Gastroenterology 125 2003 292 297 (Pubitemid 36929407)
50. S.J. Hadziyannis, N.C. Tassopoulos, E.J. Heathcote, T.T. Chang, G. Kitis, M. Rizzetto, P. Marcellin, S.G. Lim, Z. Goodman, and J. Ma et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B N Engl J Med 352 2005 2673 2681 (Pubitemid 41007822)
51. V. Cento, F. Van Hemert, M. Neumann-Fraune, C. Mirabelli, V.-C. Di Maio, R. Salpini, A. Bertoli, V. Micheli, G. Gubertini, and S. Romano et al. Anti-HBV treatment induces novel reverse transcriptase mutations with reflective effect on HBV S antigen J Infect 67 2013 303 312
52. Y.-S. Lee, Y.-H. Chung, J.A. Kim, Y.J. Jin, W.H. Park, S.E. Kim, D. Lee, J.H. Shim, K.M. Kim, and Y.S. Lim et al. rtL180M mutation of hepatitis B virus is closely associated with frequent virological resistance to adefovir dipivoxil therapy J Gastroenterol Hepatol 27 2012 300 305
53. M. Bottecchia, A. Madejón, J. Sheldon, J. García-Samaniego, P. Barreiro, and V. Soriano Hepatitis B virus genotype A2 harbours an L217R polymorphism which may account for a lower response to adefovir J Antimicrob Chemother 62 2008 626 627
54. O. Schildgen, C. Olotu, A. Funk, B. Zöllner, M. Helm, J.K. Rockstroh, and H. Sirma Selection and counterselection of the rtI233V adefovir resistance mutation during antiviral therapy J Clin Microbiol 48 2010 631 634
55. D.J. Tenney, S.M. Levine, R.E. Rose, A.W. Walsh, S.P. Weinheimer, L. Discotto, M. Plym, K. Pokornowski, C.F. Yu, and P. Angus et al. Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to lamivudine Antimicrob Agents Chemother 48 2004 3498 3507 (Pubitemid 39129351)
56. C.J. Baldick, D.J. Tenney, C.E. Mazzucco, B.J. Eggers, R.E. Rose, K.A. Pokornowski, C.F. Yu, and R.J. Colonno Comprehensive evaluation of hepatitis B virus reverse transcriptase substitutions associated with entecavir resistance Hepatology 47 2008 1473 1482 (Pubitemid 351702731)
57. M. Mukaide, Y. Tanaka, Shin-I.T., M.-F. Yuen, F. Kurbanov, O. Yokosuka, M. Sata, Y. Karino, G. Yamada, and K. Sakaguchi et al. Mechanism of entecavir resistance of hepatitis B virus with viral breakthrough as determined by long-term clinical assessment and molecular docking simulation Antimicrob Agents Chemother 54 2010 882 889
58. H. Kobashi, S. Fujioka, M. Kawaguchi, H. Kumada, O. Yokosuka, N. Hayashi, K. Suzuki, T. Okanoue, M. Sata, and H. Tsubouchi et al. Two cases of development of entecavir resistance during entecavir treatment for nucleoside-naive chronic hepatitis B Hepatol Int 3 2009 403 410
59. E. Karatayli, S.C. Karatayli, K. Cinar, S. Gokahmetoglu, K. Güven, R. Idilman, C. Yurdaydin, and A.M. Bozdayi Molecular characterization of a novel entecavir mutation pattern isolated from a multi-drug refractory patient with chronic hepatitis B infection J Clin Virol 53 2012 130 134
60. J.-L. Hu, J. Cui, J.-J. Guo, W.-L. Zhang, X.-F. Cai, Z.-W. Yuan, Q.-L. Li, X.-Y. Deng, A.-Z. Zeng, and Y. Hu et al. Phenotypic assay of a hepatitis B virus strain carrying an rtS246T variant using a new strategy J Med Virol 84 2012 34 43
61. M. Seifer, A. Patty, I. Serra, B. Li, and D.N. Standring Telbivudine, a nucleoside analog inhibitor of HBV polymerase, has a different in vitro cross-resistance profile than the nucleotide analog inhibitors adefovir and tenofovir Antiviral Res 81 2009 147 155
62. B. Qin, B. Budeus, L. Cao, C. Wu, Y. Wang, X. Zhang, S. Rayner, D. Hoffmann, M. Lu, and X. Chen The amino acid substitutions rtP177G and rtF249A in the reverse transcriptase domain of hepatitis B virus polymerase reduce the susceptibility to tenofovir Antiviral Res 97 2013 93 100
63. J. Sheldon, N. Camino, B. Rodés, A. Bartholomeusz, M. Kuiper, F. Tacke, M. Núñez, S. Mauss, T. Lutz, and G. Klausen et al. Selection of hepatitis B virus polymerase mutations in HIV-coinfected patients treated with tenofovir Antivir Ther 10 2005 727 734 (Pubitemid 41376852)
64. Y. Zhu, M. Curtis, and K. Borroto-Esoda The YMDD and rtA194T mutations result in decreased replication capacity in wild-type HBV as well as in HBV with precore and basal core promoter mutations Antivir Chem Chemother 22 2011 13 22
65. S.Y. Kwon, Y.K. Park, S.H. Ahn, E.S. Cho, W.H. Choe, C.H. Lee, B.K. Kim, S.Y. Ko, H.S. Choi, and E.S. Park et al. Identification and characterization of clevudine-resistant mutants of hepatitis B virus isolated from chronic hepatitis B patients J Virol 84 2010 4494 4503
66. W.E. Delaney 4th, H. Yang, C.E. Westland, K. Das, E. Arnold, C.S. Gibbs, M.D. Miller, and S. Xiong The hepatitis B virus polymerase mutation rtV173L is selected during lamivudine therapy and enhances viral replication in vitro J Virol 77 2003 11833 11841 (Pubitemid 37271680)
67. H. Yang, X. Qi, A. Sabogal, M. Miller, S. Xiong, and W.E. Delaney 4th Cross-resistance testing of next-generation nucleoside and nucleotide analogues against lamivudine-resistant HBV Antivir Ther 10 2005 625 633 (Pubitemid 41224954)
68. K. Das, X. Xiong, H. Yang, C.E. Westland, C.S. Gibbs, S.G. Sarafianos, and E. Arnold Molecular modeling and biochemical characterization reveal the mechanism of hepatitis B virus polymerase resistance to lamivudine (3TC) and emtricitabine (FTC) J Virol 75 2001 4771 4779 (Pubitemid 32381520)
69. W.E. Delaney 4th, R. Edwards, D. Colledge, T. Shaw, J. Torresi, T.G. Miller, H.C. Isom, C.T. Bock, M.P. Manns, C. Trautwein, and S. Locarnini Cross-resistance testing of antihepadnaviral compounds using novel recombinant baculoviruses which encode drug-resistant strains of hepatitis B virus Antimicrob Agents Chemother 45 2001 1705 1713 (Pubitemid 32466338)
70. S.K. Ono, N. Kato, Y. Shiratori, J. Kato, T. Goto, R.F. Schinazi, F.J. Carrilho, and M. Omata The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance J Clin Invest 107 2001 449 455 (Pubitemid 32167991)
71. R. Chin, T. Shaw, J. Torresi, V. Sozzi, C. Trautwein, T. Bock, M. Manns, H. Isom, P. Furman, and S. Locarnini In vitro susceptibilities of wild-type or drug-resistant hepatitis B virus to (-)-β-d-2,6-diaminopurine dioxolane and 2′-fluoro-5-methyl-β-l-arabinofuranosyluracil Antimicrob Agents Chemother 45 2001 2495 2501 (Pubitemid 32801901)
72. X. Xiong, C. Flores, H. Yang, J.J. Toole, and C.S. Gibbs Mutations in hepatitis B DNA polymerase associated with resistance to lamivudine do not confer resistance to adefovir in vitro Hepatology 28 1998 1669 1673 (Pubitemid 28549139)
73. S.K. Ono-Nita, N. Kato, Y. Shiratori, K.H. Lan, H. Yoshida, F.J. Carrilho, and M. Omata Susceptibility of lamivudine-resistant hepatitis B virus to other reverse transcriptase inhibitors J Clin Invest 103 1999 1635 1640 (Pubitemid 29534357)
74. M.-N. Brunelle, A.-C. Jacquard, C. Pichoud, D. Durantel, S. Carrouée-Durantel, J.-P. Villeneuve, C. Trépo, and F. Zoulim Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir Hepatology 41 2005 1391 1398 (Pubitemid 40770292)
75. A.-C. Jacquard, M.-N. Brunelle, C. Pichoud, D. Durantel, S. Carrouée-Durantel, C. Trepo, and F. Zoulim In vitro characterization of the anti-hepatitis B virus activity and cross-resistance profile of 2′,3′-dideoxy-3′-fluoroguanosine Antimicrob Agents Chemother 50 2006 955 961 (Pubitemid 43327800)
76. X. Qi, S. Xiong, H. Yang, M. Miller, and W.E. Delaney 4th In vitro susceptibility of adefovir-associated hepatitis B virus polymerase mutations to other antiviral agents Antivir Ther 12 2007 355 362 (Pubitemid 46787980)
77. L. Menéndez-Arias Molecular basis of human immunodeficiency virus type 1 drug resistance: overview and recent developments Antiviral Res 98 2013 93 120
78. R.A. Domaoal, M. McMahon, C.L. Thio, C.M. Bailey, J. Tirado-Rives, A. Obikhod, M. Detorio, K.L. Rapp, R.F. Siliciano, R.F. Schinazi, and K.S. Anderson Pre-steady-state kinetic studies establish entecavir 5′-triphosphate as a substrate for HIV-1 reverse transcriptase J Biol Chem 283 2008 5452 5459
79. M.A. McMahon, B.L. Jilek, T.P. Brennan, L. Shen, Y. Zhou, M. Wind-Rotolo, S. Xing, S. Bhat, B. Hale, and R. Hegarty et al. The HBV drug entecavir - effects on HIV-1 replication and resistance N Engl J Med 356 2007 2614 2621 (Pubitemid 46961006)
80. J. Sasadeusz, J. Audsley, A. Mijch, R. Baden, J. Caro, H. Hunter, G. Matthews, M.A. McMahon, S.A. Olender, and R.F. Siliciano et al. The anti-HIV activity of entecavir: a multicentre evaluation of lamivudine-experienced and lamivudine-naive patients AIDS 22 2008 947 955 (Pubitemid 351652245)
81. E. Michailidis, K.A. Kirby, A. Hachiya, W. Yoo, S.P. Hong, S.-O. Kim, W.R. Folk, and S.G. Sarafianos Antiviral therapies: focus on hepatitis B reverse transcriptase Int J Biochem Cell Biol 44 2012 1060 1071
82. N. Warner, and S. Locarnini The antiviral drug selected hepatitis B virus rtA181T/sW172* mutant has a dominant negative secretion defect and alters the typical profile of viral rebound Hepatology 48 2008 88 98 (Pubitemid 351975534)
83. S.H. Ahn, Y.K. Park, E.-S. Park, J.H. Kim, D.H. Kim, K.-H. Lim, M.S. Jang, W.H. Choe, S.Y. Ko, and I.-K. Sung et al. The impact of the hepatitis B virus polymerase rtA181T mutation on replication and drug resistance is potentially affected by overlapping changes in surface gene J Virol 2014 10.1128/JVI.00635-14
84. Y.S. Lim, T.H. Lee, N.Y. Heo, J.H. Shim, H.C. Lee, and D.J. Suh Entecavir plus adefovir combination treatment for chronic hepatitis B patients after failure of nucleoside/nucleotide analogues Antivir Ther 17 2012 53 60
85. X. Wang, C. Zhang, Y. Zhu, Y. Xiong, and Y. Wang Efficacy of 2 years of entecavir plus adefovir therapy in patients with chronic hepatitis B who had failed on prior nucleos(t)ide analog treatment Antiviral Res 103 2014 71 77
86. F. Li, H. Maag, and T. Alfredson Prodrugs of nucleoside analogues for improved oral absorption and tissue targeting J Pharm Sci 97 2008 1109 1134
87. M.-F. Yuen, S.-H. Lee, H.-M. Kang, C.R. Kim, J. Kim, V. Ngai, and C.-L. Lai Pharmacokinetics of LB80331 and LB80317 following oral administration of LB80380, a new antiviral agent for chronic hepatitis B (CHB), in healthy adult subjects, CHB patients, and mice Antimicrob Agents Chemother 53 2009 1779 1785
88. C.L. Lai, S.H. Ahn, K.S. Lee, S.H. Um, M. Cho, S.K. Yoon, J.W. Lee, N.H. Park, Y.O. Kweon, and J.H. Sohn et al. Phase IIb multicentred randomised trial of besifovir (LB80380) versus entecavir in Asian patients with chronic hepatitis B Gut 2013 10.1136/gutjnl-2013-305138
89. Y. Hu, X. Cheng, F. Cao, A. Huang, and J.E. Tavis β-Thujaplicinol inhibits hepatitis B virus replication by blocking the viral ribonuclease H activity Antiviral Res 99 2013 221 229
90. J.E. Tavis, X. Cheng, Y. Hu, M. Totten, F. Cao, E. Michailidis, R. Aurora, M.J. Meyers, E.J. Jacobsen, M.A. Parniak, and S.G. Sarafianos The hepatitis B virus ribonuclease H is sensitive to inhibitors of the human immunodeficiency virus ribonuclease H and integrase enzymes PLoS Pathog 9 2013 e1003125
91. Y.X. Wang, Y.M. Wen, and M. Nassal Carbonyl J acid derivatives block protein priming of hepadnaviral P protein and DNA-dependent DNA synthesis activity of hepadnaviral nucleocapsids J Virol 86 2012 10079 10092
92. L. Belloni, L. Allweiss, F. Guerrieri, N. Pediconi, T. Volz, T. Pollicino, J. Petersen, G. Raimondo, M. Dandri, and M. Levrero IFN-α inhibits HBV transcription and replication in cell culture and in humanized mice by targeting the epigenetic regulation of the nuclear cccDNA minichromosome J Clin Invest 122 2012 529 537
93. J. Lucifora, Y. Xia, F. Reisinger, K. Zhang, D. Stadler, X. Cheng, M.F. Sprinzl, H. Koppensteiner, Z. Makowska, and T. Volz et al. Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA Science 343 2014 1221 1228